Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintained a price target of $18.
June 17, 2024 | 9:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Cogent Biosciences and maintained a price target of $18, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a price target at $18 by a reputable analyst suggests strong confidence in the company's future performance. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100